EUVIMEDEUVIMED entdecken
Crossref

The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis

Mete PEKDİKER

Interdisciplinary Medical Journal · 2023

DOI: 10.17944/interdiscip.1351896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Interdisciplinary Medical Journal, 2023. Verfasst von Mete PEKDİKER. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Rituximab is an effective biological agent for treating patients with rheumatoid arthritis (RA). Rheumatologists can avoid rituximab therapy because of infusion-related reactions (IRR). There is a lack of data about rituximab-related IRR, especially in rituximab-naïve patients with RA; therefore, we aimed to determine the frequency and associated factors of rituximab-related IRR in these patients.

Methods

Baseline demographic, laboratory, and treatment data were noted. One course of rituximab was used in two infusions to 95 rituximab-naïve patients with RA. Standardized premedication was administered before infusions. Rates, severity, and management of IRR were recorded. Efficacy and infections were also noted if there were.

Results

Ninety-four of 95 patients completed the rituximab course successfully. We observed a total of 23 IRRs in 20 patients. The frequency of IRR was 12.1%, and serious IRR was 0.52%. Grade 1-2-3 IRRs had a rate of 52.2%, 30.4%, and 17.4%, respectively; grade 4 or 5 IRR wasn’t detected. Age <60 years, anti-CCP <200U/ml and absence of biologic agent use before rituximab was significantly higher in patients with IRR than without IRR (p=0.01, p=0.002, p=0.01 respectively). We found out that if only the disease age is above 60 months, it is protective against IRR as per the results of multivariate model analysis.

Conclusion

Results supported that rituximab is a safe biological agent option for patients with RA at secondary central hospitals. Identified risk factors of IRR need to be corroborated in larger studies for safer rituximab therapy.

Zitieren

APA

PEKDİKER, M. (2023). The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis. Interdisciplinary Medical Journal. https://doi.org/10.17944/interdiscip.1351896

Vancouver

PEKDİKER M. The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis. Interdisciplinary Medical Journal. 2023. doi:10.17944/interdiscip.1351896

BibTeX
@article{PEKDKER2023,
  author = {PEKDİKER, Mete},
  title = {The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis},
  journal = {Interdisciplinary Medical Journal},
  year = {2023},
  doi = {10.17944/interdiscip.1351896}
}
Kostenlos starten →